Cubist Systematic Strategies LLC Has $769,000 Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Cubist Systematic Strategies LLC reduced its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 65.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 45,885 shares of the company's stock after selling 88,235 shares during the period. Cubist Systematic Strategies LLC's holdings in Centessa Pharmaceuticals were worth $769,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in CNTA. JPMorgan Chase & Co. raised its stake in shares of Centessa Pharmaceuticals by 1,969.2% during the third quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company's stock valued at $2,173,000 after acquiring an additional 129,335 shares during the last quarter. Barclays PLC boosted its holdings in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. Diadema Partners LP purchased a new stake in Centessa Pharmaceuticals in the fourth quarter worth approximately $2,209,000. ADAR1 Capital Management LLC boosted its holdings in Centessa Pharmaceuticals by 561.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 154,027 shares of the company's stock worth $2,580,000 after purchasing an additional 130,725 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Centessa Pharmaceuticals by 13.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,095,924 shares of the company's stock worth $18,357,000 after acquiring an additional 130,312 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on CNTA shares. Piper Sandler began coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price for the company. Chardan Capital began coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued a "buy" rating and a $30.00 price objective on the stock. Morgan Stanley restated an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 price objective on the stock. Finally, Guggenheim reiterated a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $27.00.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 2,080 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $14.01, for a total value of $29,140.80. Following the completion of the sale, the general counsel now owns 105,386 shares in the company, valued at $1,476,457.86. This represents a 1.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David M. Chao sold 7,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $17.17, for a total transaction of $120,190.00. Following the completion of the sale, the insider now owns 225,007 shares in the company, valued at $3,863,370.19. This represents a 3.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 171,398 shares of company stock valued at $2,697,422. Insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Stock Down 1.0%

Shares of CNTA stock traded down $0.12 on Monday, reaching $12.39. 237,625 shares of the stock were exchanged, compared to its average volume of 635,819. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -8.10 and a beta of 1.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The business's 50 day moving average price is $13.48 and its 200 day moving average price is $15.58.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.15. As a group, sell-side analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.